Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))

The authors regret that some author affiliations and the name of one of the authors, Corina Oprea, were incorrect. Please find below the correct author list and affiliations. Irene M. Ghobrial¹, Paula Rodríguez-Otero², Youngil Koh³, Joaquín Martínez-López⁴, Gurdeep Parmar⁵, Miles Prince⁶, Hang Quach⁷, Javier de la Rubia⁸, Emil Hermansen⁹, Vania Hungria¹⁰, Sevgi Kalayoglu Besisik¹¹, Jin Seok Kim¹², Xavier Leleu¹³, Valdas Peceliunas¹⁴, Fredrik Schjesvold¹⁵, Franck Dubin¹⁶, Christine Devisme¹⁶, Lucie Lepine¹⁷, Sandrine Macé¹⁶, Corina Oprea¹⁶, María-Victoria Mateos^{18 1}Dana-Farber Cancer Institute, Boston, MA, USA ²Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain ³Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea ⁴Departamento de Hematología, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain ⁵Illawarra Cancer Care Centre, Wollongong, NSW, Australia ⁶Immunology and Molecular Oncology, Epworth Healthcare and University of Melbourne, Melbourne, Vic, Australia ⁷University of Melbourne, St Vincent's Hospital, Melbourne, Australia ⁸Hematology Department, University Hospital La Fe, Valencia, Spain ⁹Department of Haematology, Zealand University Hospital, Roskilde, Denmark ¹⁰Department of Hematology and Oncology, Clínica São Germano, São Paulo, Brazil ¹¹Department of Internal Medicine, Division of Hematology, Istanbul University Medical Faculty, Istanbul, Turkey ¹²Department of Hematology, Severance Hospital, Seoul, Republic of Korea ¹³Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France ¹⁴Hematology, Oncology and Transfusion Medicine Department, Vilnius University Hospital, Vilnius, Lithuania ¹⁵Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway ¹⁶Sanofi, Vitry-sur-Seine, France ¹⁷Excelya, Boulogne-Billancourt, France ¹⁸Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain The authors would like to apologize for any inconvenience caused. DOI of original article: 10.1016/S2152-2650(21)02264-3 *Corresponding author: Irene Ghobrial, Dana-Farber Cancer Institute, Boston, MA, USA Email address: Irene_Ghobrial@DFCI.HARVARD.EDU